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Introduction
Respiratory infections caused by Legionella pneumophila 
(Lpn), Mycoplasma pneumoniae (Mpn) and Chlamydia 
pneumoniae (Cpn) may account for up to 22% of all cases of 
community-acquired pneumonia (CAP) worldwide [1]. These 
infections may occur in outbreak situations or as sporadic 
cases.   Often referred to as etiologic agents of “atypical 
pneumonia”, Lpn, Mpn and Cpn are not detected during routine 
microbiologic work-up, and typically require special testing 
requests.  Respiratory fluoroquinolones, or macrolide plus beta 
lactam class antibiotics, are used to treat patients presenting 
with community acquired pneumonia initially; thus, a rapid and 
accurate diagnosis allows for targeted antimicrobial therapy [2].
Diagnosis of these agents has undergone an evolution from 
detection by isolation in culture [3-5], serologic methods 
[6], detection of urinary antigen for Lpn [7] and eventually, 
molecular detection in respiratory specimens [8].  Molecular-
based assays were initially reported for Lpn by Edelstein et. al., 
[9] in 1986, for Mpn by Bernet et. al., in 1989 [10] and for Cpn 
by Holland et. al. in 1990 [11].   Since that time, additional assays 
have been described and studies have concluded that due to the 
lower level of sensitivity of non-molecular detection of these 
agents, molecular detection in respiratory specimens is the 
preferred test for rapid diagnosis [12].  This will most often 
lead to the initiation of appropriate antimicrobial therapy [1]. 
While macrolides remain the treatment choice for CAP due to 
Mpn, it is worth noting that resistance has been found in the 
USA.  In a study published in 2015, 13.2% of 91 positive patient 
specimens demonstrated resistance to macrolides such as 
erythromycin  [13].  Emerging resistance with Mpn reinforces 
the need for rapid and accurate diagnostics performed directly 
from respiratory specimens.  In this way, treatment failures 
can be effectively managed based on accurate and specific 
identification of one or more pathogens.
Subsequently, these three assays have been described in 
multiplexed format by several investigators [14, 15] and two 
of these targets, Mpn and Cpn, are currently included in two 
FDA-cleared assays, the FilmArray Respiratory Panel (Biofire 
Diagnostics, Salt Lake City, UT) and the NxTAG Respiratory 
Pathogen Panel (Luminex, Inc., Austin, TX).  Recently, CMS has 
published draft statements about reducing reimbursements for 
highly multiplexed panels such as these [16], making smaller, 
targeted panels more appealing to laboratories and health care 
providers.
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Abstract
Background: Mycoplasma pneumoniae (Mpn), Chlamydia pneumoniae (Cpn), and Legionella 
pneumophila (Lpn) can cause both epidemic and endemic occurrences of acute respiratory 
disease and are responsible for up to 22% of cases of community acquired pneumonia. Due to 
the limited availability of FDA-approved molecular diagnostic assays, we developed and evaluated 
a multiplexed Real-time PCR assay for the detection of these agents in two respiratory specimen 
types on the Luminex ARIES® instrument. The instrument provides for nucleic acid extraction plus 
PCR amplification and target detection in the same cassette. The ARIES® instrument generates a 
cycle threshold value and a confirmatory melt curve value for each reaction, including results for 
an internal sample processing control.  The limit of detection for Mpn, Cpn and Lpn, was 100 CFU/
mL, 1000 CFU/mL and 100 CFU/mL, respectively. In addition, accuracy, precision, specificity and 
stability studies were conducted to validate the assay for diagnostic use. Between November 2016 
and June 2017, a total of 836 patient specimens were processed in our reference laboratory, with six 
positive Mpn and two positive Lpn.  No specimens were positive for Cpn during this time period. The 
availability of a robust multiplex PCR assay greatly enhances the ability to rapidly diagnose infections 
caused by these three agents causing atypical pneumonia.
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ORIGINAL RESEARCH
We report here the development and evaluation of a 
multiplexed PCR assay for the detection of Mpn, Cpn and Lpn 
in oropharyngeal swabs (OP) and broncho-alveolar lavage 
(BAL) fluid specimens on the Luminex ARIES® instrument.  The 
ARIES® is a stand-alone, open-platform instrument in which the 
assay uses Multicode®-RTx Technology (Luminex, Inc., Austin, 
TX) with the synthetic base pair isoC:isoG in a probe-free PCR 
assay.  Because of the hydrogen bonding pattern between these 
two synthetic bases, they can only bind to each other, adding 
specificity to the DNA amplification process.  This closed system 
greatly simplifies the process of extraction, amplification and 
detection within a single cassette while remaining robust for 
diagnostic testing purposes.  
Methods
Reagents: Proprietary MultiCode-Rtx® primer pairs for Mpn, 
Lpn and Cpn (Part numbers: 3927, 3926 and 3925) were 
obtained from Luminex. Mouse Hepatitis Virus Control Primer 
Set 5 (MHV5, proprietary sequence, Part Number: 3806) was 
used to amplify the Sample Processing Control (SPC, used to 
confirm extraction, amplification and to detect PCR inhibition). 
The melt calibrator function allowed for calibration of detected 
melting temperatures (Tm) in the cassette based on MHV5 
amplification. ReadyMix® tubes (Part Number 3697, Luminex, 
Austin, TX) contain all reagents needed to run PCR on the 
Luminex ARIES® instrument. SnotBuster® was purchased from 
COPAN (Catalog number 097CE.A, Murietta, CA). Universal 
Transport Media (UTM) and flocked swabs were purchased 
from Quidel/Diagnostic Hybrids (Part Number 402C, San 
Diego, CA).
Primer Pool Preparation: The four primer sets (Mpn, Lpn, Cpn 
and MHV5) were purchased in 100 μL aliquots.  Once thawed, 
primers were given a quick spin and equal volumes of each 
primer were combined to make the multiplex primer set. Pooled 
primers were stored at -20°C in aliquots of 80 μL.
Organisms: Mpn (ATTC®, Catalog number: 15531TT), Cpn 
(titered clinical isolate) and Lpn (titered clinical isolate) were 
used for sensitivity and precision studies. Mpn was grown as 
described previously [17]. Cpn was propagated in Hep2C cells, 
then harvested, purified and titered as described previously 
[18]. Lpn was grown on Buffered Charcoal Yeast Extract (BCYE) 
agar plates and colonies were suspended in saline.  Suspensions 
were adjusted to a 0.5 McFarland Standard (approximately 
1.5x108 CFU/mL) prior to diluting in UTM for PCR studies. 
Specimens: Sensitivity, accuracy, precision, stability and 
specificity studies were assessed using BAL fluid and OP swabs 
which were collected from healthy volunteers and patients with 
pneumonia. These specimens were used as matrices after testing 
negative for Mpn, Cpn and Lpn by both our laboratory-validated 
PCR test and by the ARIES® PCR assay. For each PCR assay, 
200 µL of OP swab specimens collected in universal transport 
media were used. BAL fluid specimens were pre-treated with 
SnotBuster® before loading into cassettes by adding 200 µL of 
specimen to a 1.5 mL microtube and 200 µL of SnotBuster®, 
then mixed by vortexing for 10 seconds.  After incubating at 
room temperature for 15 minutes, the SnotBuster® pre-treated 
BAL fluid specimens were centrifuged using a Thermo-Fisher 
mini centrifuge (mySPIN 6) at 2000 x g for one minute.  After 
centrifugation, 390 µL (to avoid any pelleted material) of the 
pre-treated BAL supernatant was used for the PCR assay.
Cassette Preparation: Eight (8) µL of multiplex primer mix were 
added to each ReadyMix® tube, then attached to the ARIES® 
cassette. ARIES® Cassettes (Part Number: 50-10026, Luminex) 
hold the extraction reagents and Sample Processing Control 
(SPC). The samples to be tested were added to the cassette and 
loaded onto the ARIES, then the extraction, PCR reaction, and 
result generation proceeded automatically.
Sensitivity experiments: For sensitivity, the Limit of Detection 
(LOD, or cutoff) was determined for three targets (Mpn, Cpn 
and Lpn) in both BAL fluid and OP swab specimen types that 
were negative by both PCR assays.  Mpn, Cpn and Lpn were 
spiked individually into each specimen type at concentrations 
of 1 x 105 CFU/mL, 1 x 104 CFU/mL, 1 x 103 CFU/mL, 100 CFU/
mL, 10 CFU/mL, and 1 CFU/mL then tested as described above. 
This sensitivity assay was conducted three times independently. 
Accuracy experiments: For the accuracy study, archived patient 
specimens that were tested previously using an in-house 
validated laboratory-developed test (LDT) PCR assay were 
tested on the ARIES® instrument.  All the positive samples were 
previously PCR-positive for Mpn, Lpn or Cpn in our laboratory 
from patients for whom a pneumonia infection was detected 
using the LDT PCR.  Twenty-three (23) Mpn-positive samples 
(either OP swab or BAL fluid specimens), nineteen (19) Lpn-
positive samples (all BAL fluid specimens) and one Cpn-positive 
patient BAL fluid specimen were tested. In addition, DNA from 
eleven (11) different Cpn-positive patients was spiked into 
ReadyMix® tubes for OP swab specimens, and DNA from ten 
(10) Cpn-positive patients was spiked into ReadyMix® tubes 
for BAL fluid specimens, then placed in the extraction cassette 
containing negative specimen and tested. For negative controls, 
thirteen (13) negative patient BAL fluid specimens and seven (7) 
negative patient OP swab specimens were tested.
Precision experiments: Reproducibility studies to determine 
precision were done using both BAL fluid and OP swab specimen 
types for all three targets spiked with a concentration of 1 x 103 
CFU/mL. One positive control containing all three targets (as 
well as a negative control) were run on different days in order to 
obtain ten successful runs with different operators for both OP 
swab and BAL fluid specimen types previously determined to be 
negative by both PCR assays.
Stability experiments: Specimen stability studies were 
conducted by storage of spiked BAL fluid and OP swab specimen 
types (1 x 103 CFU/mL, in duplicate) at 4°C, and these samples 
were assayed daily for eight days.
Specificity experiments: Twelve bacterial organisms, including 
Enterococcus faecalis, Escherichia coli, Staphylococcus 
aureus, Proteus mirabilis, Aerococcus viridans, Streptococcus 
agalactiae, Moraxella catarrhalis, Staphylococcus epidermidis, 
Streptococcus pyogenes, Streptococcus pneumoniae, Klebsiella 
pneumoniae and Burkholderia cepacia, kindly provided by 
Dr. Alan Junkins, Norton Healthcare, Louisville, KY were 
used for specificity determination in both OP swab and BAL 
fluid specimens. Legionella bozemanii, L. pneumophila 
Togus-1, L. pneumophila Bloomington-2, and L. pneumophila 
Dallas 1E were provided by the laboratory of Dr. Richard 
Miller, Environmental Safety Technologies. Louisville, KY  L. 
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pneumophila Knoxville (ATCC® 33153, strain type) and L. 
pneumophila Philadelphia (ATCC® 33152, strain type) were 
obtained from the American Type Tissue Collection (ATCC, 
Manassas, VA).  A single colony was selected from freshly 
sub-cultured plates using a sterile loop; the loop was used 
to inoculate two different specimen types determined to be 
negative for Mpn, Cpn and Lpn (200 µL of OP swab or BAL 
fluid).  In addition, several respiratory viruses were tested in 
OP and/or BAL matrices.  Five clinical samples from patients 
previously diagnosed with viral infections using the FilmArray® 
Respiratory Virus Panel (BioFireDX, Salt Lake City, UT) were 
tested.  Titered respiratory virus samples from Zeptometrix 
(Buffalo, NY) were tested, including Influenza A/H3 (Catalog 
#0810238CF, Texas/50/12), Human Metapneumovirus 
(Catalog #0810156CF, hMPV 3/Type B1), Coronavirus 229E 
(Catalog #0810229CF), Adenovirus B (Catalog #0810062CF, 
Type 3/Species B), and Influenza A/H1N1 (Catalog 
#0810244CF, Brisbane/59/07), all at titers >105 and assayed for 
Tissue Culture Infecive Dose (TCID50). OP swab and BAL fluid 
specimens were tested in duplicate to assess specificity. 
Data Analysis: MS Excel was used to calculate standard 
deviations for replicate experiments, while MEDCALC 
Diagnostic Test Evaluation was used to determine analytic 
sensitivity and specificity [19]. The Luminex ARIES® instrument 
used SYNCT® software and User Defined Protocol (UDP) 
module to set assay parameters and interpret run results. The 
SYNCT® software was installed on an external computer for 
detailed data analysis and editing of Ct and Tm cutoff values. 
After completing data analysis and PCR assay validation, the cut 
off values were fixed and locked in the SYNCT® software assay 
file. Next, the assay file was loaded on the ARIES® instrument 
for subsequent diagnostic laboratory testing (Table 1). In order 
for a specimen to be called positive for Lpn, Mpn or Cpn, the 
following conditions had to be met:
1. The SPC for any given specimen must have a valid Ct value 
and Tm to exclude sample inhibition.
2. The specimen must have Ct and Tm values in the 
established range for each organism. 
Table 1 Amplification and Melt Curve Settings for ARIES®
Results
Sensitivity: Sensitivity was expressed as the cutoff for all three 
targets. All three organisms were serially diluted ten-fold from 
1 x 105 to 1 x 100 CFU/mL for these experiments. Results are 
represented as mean ± standard deviation, from three replicate, 
independent experiments. The cutoff results for Mpn, Cpn 
and Lpn were 100 CFU/mL, 1000 CFU/mL and 100 CFU/mL, 
respectively (Table 2). Table 2 shows only the cutoff values for 
BAL fluid specimens, but similar results were observed with OP 
swab specimens for each organism (data not shown).
Table 2 Assay Sensitivity for Mpn, Cpn and Lpn in BAL Specimens
Accuracy: Twenty-three of 23 previous Mpn-positive samples 
were likewise positive with the ARIES® assay, giving a 100% 
sensitivity (Table 3). Twenty-one different previously Cpn-
positive patient (11 OP swab and 10 BAL fluids) samples were 
positive using the ARIES® assay, giving a 100% accuracy (Table 
3).  All 19-previous positive Lpn-samples were positive using 
the ARIES® system as well, giving a 100% sensitivity (Table 3). 
All 19 patient samples negative for both BAL fluid and OP swab 
specimen types were also negative using the ARIES® system, 
but the SPC was positive for all samples, indicating there was no 
inhibition of PCR (data not shown).  Sensitivity and specificity 
are shown in Table 3. 
Table 3 Accuracy Results for the Mpn, Cpn and Lpn PCR Assay
Precision: Mpn, Cpn and Lpn (1 x 103 CFU/mL) were spiked 
into either negative BAL fluid or OP swab samples and used 
as positive controls by different laboratory technologists on 
different days. Reproducibility of the resultant Ct and Tm values 
for four targets (including the MHV5 SPC) did not change over 
the course of the different testing periods by different operators. 
The standard deviation (SD) for Mpn, Cpn and Lpn Ct values 
were less than 2.5, and SD Tm values less than 0.15, on both 
BAL fluid and OP swab specimens (Table 4). Negative controls 
were negative for all three targets. All internal control results 
(SPC) indicated no inhibition on either BAL or OP specimen 
types/matrices (individual run data not shown).
Table 4 Precision Studies for the Mpn, Cpn and Lpn PCR Assay
Stability: Mpn, Cpn and Lpn (1 x 103 CFU/mL of each 
organism) were spiked into both BAL fluid and OP swab 
matrices and tested in duplicate for seven days, and in singlet on 
day eight. After preparing the sample on day one, it was stored 
in the refrigerator at 4°C (±2°C). The SD for all Ct values over 
eight days was less than 1.5 for both specimen types. Expected 
Ct and Tm values for each organism were observed each day of 
testing, whether they were spiked into BAL fluid or OP swab 
specimens (data not shown).  Thus, specimens demonstrated 
stability at refrigerated temperatures for up to eight days after 
collection. 
Specificity: Twelve different bacterial organisms and several 
common respiratory viruses were spiked into BAL fluid and OP 
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swab matrices and tested Mpn,Cpn and Lpn primers (Table 
5). In addition, five specimens from patients diagnosed with 
respiratory virus illnesses were tested using the Mpn, Cpn 
and Lpn multiplex PCR assay.  There was no cross-reactivity 
observed, and the results demonstrated that these primers 
were specific to Mpn, Cpn and Lpn.  In addition, Legionella 
pneumophila strains of various serotypes and Legionella 
bozemanii were tested to gauge genus, species and serotype 
detection (Table 5).  We found that multiple serotypes of 
Lpn were detected, but not L. bozemanii, indicating that L. 
pneumophila serotypes other than 01 could be identified by this 
assay. 
Table 5 Specificity Studies for the Mpn, Lpn and Cpn PCR assay
Performance with Clinical Specimens: Between 
November 2016 and June 2017, a total of 836 patient specimens 
were processed in our reference laboratory, with six positive 
Mpn and two positive Lpn, giving a 0.72% positivity rate 
(data not shown). No specimens had detectable Cpn.  It was 
noteworthy that samples rarely had to be retested due to invalid 
results on the ARIES® instrument.  Out of 1064 specimens tested 
with the multiplex Mpn, Lpn and Cpn PCR assay, only 50 invalid 
results occurred, giving a 4.7% invalid rate.  When respiratory 
samples did give invalid results, it was typically in BAL fluid 
specimens with excessive blood or mucus, and diluting 1:2 or 1:4 
with saline prior to re-testing gave valid results. 
Example readout from ARIES® instrument: The SPC 
must show the expected amplification and melt curve values (Ct 
and Tm values) in patient samples that are negative (negative 
control example, Figure 1A). If the patient sample or positive 
control is positive for any target (Mpn, Cpn or Lpn), the ARIES® 
result shows the positive sample amplification (Ct value) and 
melt curve (Tm) data but will not show Ct and Tm values for the 
SPC (positive control example, Figure 1B). This is hardcoded 
in the software for ARIES® instrument. The SPC amplification 
and melt curve including Ct and Tm values can be obtained from 
SYNCT® software, when needed.
Figure 1A Negative control result. Sample data from ARIES® instrument 
with a negative control illustrating the amplification curve and melt 
temperature for the internal control (SPC). 
Figure 1B Positive control result. Sample data from ARIES® instrument 
with a positive control illustrating the amplification curve and melt 
temperature for Mpn, Cpn, and Lpn (SPC).
Discussion
The Luminex ARIES® instrument performs extraction and 
generates PCR amplification and melt curves for each target 
organism, plus the sample processing control, in a single 
cassette.  After addition of primers to ReadyMix® and specimen 
to the cassette, the PCR amplification is completed in two 
hours.  Due to the limited availability of FDA-approved assays 
that detect a small panel of atypical pneumonia organisms, 
we present here the results of our laboratory validation of this 
multiplex PCR assay that detects Mpn, Cpn and Lpn.
The established limits of detection for Mpn, Cpn and Lpn were 
100 CFU/mL, 1000 CFU/mL and 100 CFU/mL, respectively 
for both BAL and OP specimen types.  This is similar sensitivity 
to previously published studies using NP swabs [20] or NP 
aspirates [21] in a multiplex PCR assay for Mpn, Cpn and Lpn 
targets.  For example, Miyashita et al. [20] found using their 
multiplex PCR assay with a Micro-Chip Electrophoresis Analysis 
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E. faecalis OP 35.5 83.8 Negative for Mpn, Cpn, Lpn 
E. coli OP 37.3 83.9 Negative for Mpn, Cpn, Lpn 
S. aureus OP 36.2 83.8 Negative for Mpn, Cpn, Lpn 
P. mirabilis OP 35.6 83.8 Negative for Mpn, Cpn, Lpn 
A. viridans OP 37.3 83.8 Negative for Mpn, Cpn, Lpn 
S. agalactiae OP 35.0 83.8 Negative for Mpn, Cpn, Lpn 
M. catarrhalis OP 34.6 84.1 Negative for Mpn, Cpn, Lpn 
S. epidermidis OP 37.3 83.8 Negative for Mpn, Cpn, Lpn 
S. pyogenes OP 35.9 84.1 Negative for Mpn, Cpn, Lpn 
S. pneumoniae OP 35.5 84.1 Negative for Mpn, Cpn, Lpn 
K. pneumoniae OP 38.1 83.9 Negative for Mpn, Cpn, Lpn 
B. cepacia OP 37.3 83.9 Negative for Mpn, Cpn, Lpn 
Influenza A/H1N1 
(Zeptometrix) 
OP 33.5 84.2 Negative for Mpn, Cpn, Lpn 
Influenza A/H3 (Zeptometrix) OP 38 84.3 Negative for Mpn, Cpn, Lpn 
Influenza A/H3 
(clinical) 
OP 33.4 83.8 Negative for Mpn, Cpn, Lpn 
Rhinovirus/ Enterovirus 
(clinical) 
OP 35 83.5 Negative for Mpn, Cpn, Lpn 
Parainfluenza-4 (clinical) OP 33 83.6 Negative for Mpn, Cpn, Lpn 
Human Metapneumovirus 
(clinical) 
OP 37.2 83.3 Negative for Mpn, Cpn, Lpn 
Human Metapneumovirus 
(Zeptometrix) 
OP 34.3 84.3 Negative for Mpn, Cpn, Lpn 
Coronavirus OC4 (clinical) OP 32.9 83.6 Negative for Mpn, Cpn, Lpn 
Coronavirus 229E 
(Zeptometrix) 
OP 33.5 84.2 Negative for Mpn, Cpn, Lpn 
Adenovirus 3/B 
(Zeptometrix) 
OP 31.7 84.3 Negative for Mpn, Cpn, Lpn 
L. bozemanii OP 33.6 83.8 Negative for Mpn, Cpn, 
Lpn 
L. pneumphila Togus-1; 
Serogroup 02 
OP 33.2 84.4 Negative for Mpn, Cpn, 





OP 38.3 84.4 Negative for Mpn, Cpn, 
Positive for Lpn (Ct 
22.4/Tm 71.4) 
L. pneumonphila Dallas 1E; 
Serogroup 05 
OP 38.5 83.4 Negative for Mpn, Cpn, 
Positive for Lpn (Ct 
23.7/Tm 71.9) 
L. pneumophila Knoxville; 
Serogroup 01 (ATCC® 
33153) 
OP 38.8 84.4 Negative for Mpn, Cpn, 
Positive for Lpn(Ct 
19.8/Tm 71.5) 
L. pneumophila 
Philadelphia; Serogroup 01 
(ATCC® 33152) 
 
OP 35.4 84.3 Negative for Mpn, Cpn, 
Positive for Lpn(Ct 
20.4/Tm 72) 
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System, they could detect 100 copies per mL of Mpn, Cpn and 
Lpn.  When they tested 208 patients with community acquired 
pneumonia using nasal swabs, the multiplex PCR assay detected 
14/15 patients with Cpn, 10/10 with Mpn and 8/8 with Lpn 
infections [20].  Similarly, Lam et al demonstrated a sensitivity 
range of 1000 to 10,000 CFU/mL with a multiplex nested PCR 
assay on the ABI FAST® PCR system [21].  Using 303 clinical 
specimens (NP aspirates), they found a 48.5% positivity rate for 
detecting Mpn, Cpn, Lpn or Adenovirus [21].  When previously 
positive specimens were tested on the ARIES® system with the 
PCR assay described here, each organism was correctly detected 
compared to the results from the prior test platform used in 
our laboratory, giving 100% sensitivity.  Precision results were 
excellent when the same specimens were tested on different 
days by different testing personnel, as indicated by very small 
standard deviations.
A panel of twelve different bacterial organisms and several 
common respiratory viruses were tested using BAL fluid and OP 
swab matrices. There was no cross-reactivity observed, thereby 
demonstrating that these primers were specific to Mpn, Cpn and 
Lpn. Because we tested L. pneumophila strains representing 
serogroups 01, 02, 03, and 05, as well as L. bozemanii, we 
demonstrated primer specificity for L. pneumophila; however, 
we observed broader detection than L. pneumophila urine 
antigen assays that target only serogroup 01. Finally, stability 
studies indicated that after storage for eight days at 4°C, positive 
specimens processed by the ARIES® instrument were detected. 
Future studies could address the stability at -20°C and -80°C for 
long-term specimen storage. 
Taken as a whole, these results indicate that the Luminex 
ARIES® PCR assay is quite robust.  During the validation and 
subsequent use as a diagnostic PCR assay, a few limitations 
were noted.  For BAL fluid specimens, excess mucus was found 
to cause invalid results on rare occasions (50/1064, or 4.7%). 
In these cases, diluting the specimen prior to mixing with 
SnotBuster® and re-running the diluted specimen eliminated 
the inhibition observed in the initial specimen.  This was not 
observed with OP swab specimens, which are typically free of 
excess mucus.  The Luminex ARIES® instrument uses SYNCT® 
software to set parameters and interpret run results.  Mastery 
of this software requires dedicated time and effort; however, 
technical support, assistance and training is available from 
the manufacturer.  Finally, the ARIES® instrument uses 
universal cycling conditions to facilitate multiplex PCR assay 
development.  If cycling conditions need to be changed for a 
particular assay, they can be modified, but then separate assays 
would need to be performed using different modules on the 
ARIES® instrument. 
The data presented here illustrate the performance 
characteristics of a multiplex PCR assay for three agents of 
atypical pneumonia. The MultiCode-Rtx® chemistry enables the 
detection of almost any nucleic acid target due the highly specific 
binding of IsoC and IsoG base pairs, without the need for an 
additional fluorescent-tagged oligo or probe.  The format is an 
improvement over previously published processes due to the 
elimination of a separate extraction step for clinical specimens. 
Furthermore, due to the combination of ReadyMix® tubes and 
cassettes used by the ARIES® instrument, minimal technologist 
time is required because extraction, amplification and detection 
occur within the cassette.  This format reduces risk of cross-
contamination and amplicon contamination significantly and 
provides both a Ct value and a melt curve value, adding specificity 
to the assay.  The ARIES® system is easy to use with Luminex 
analyte specific reagents (ASR). Luminex application specialists 
provide general guidance to aid in new assay development, 
which is extremely valuable to smaller clinical laboratories with 
limited resources.  As an open PCR platform with the capacity to 
design primers for multiple targets as well as internal controls, 
this system offers flexibility for laboratories.  This feature 
is important during a time when reimbursement for highly 
multiplexed assays is at risk [16], and more targeted panels 
(like the atypical pneumonia assay described here) are favored 
currently.  In the current climate, it is critical that laboratories 
calculate cost per test versus reimbursement, either through 
third party insurance or direct billing for laboratory services, to 
remain viable.  Open platforms, such as the ARIES® system, can 
help lower direct costs in the face of declining reimbursements.
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